{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:27:54Z","timestamp":1781008074941,"version":"3.54.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Peripheral T-cell lymphoma (PTCL) is featured with a poor survival outcome. China has approved chidamide, an oral novel histone deacetylase inhibitor, for patients diagnosed with relapsed or refractory PTCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We compared the benefit of traditional chemotherapy alone and a combination of chidamide and traditional chemotherapy against newly diagnosed PTCL. Prognostic factors related to progression and survival in patients diagnosed with untreated PTCL were also investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>104 patients with newly diagnosed PTCL were enrolled and divided into chemotherapy (ChT) group and chemotherapy combined with chidamide (ChT+C) group. Survival curves were plotted by the Kaplan-Meier method. Univariate and multivariate analysis were conducted with Log-rank test and Cox\u2019s proportional hazard regression. Subgroup analysis and interaction tests were conducted to evaluate factors associated with prognostic differences between ChT and ChT+C groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with patients in ChT group, those in ChT+C group had superior progression-free survival (PFS) (<jats:italic>p<\/jats:italic>=0.047). However, there was no significantly statistical difference observed between the two groups in overall survival (OS) (<jats:italic>p<\/jats:italic>=0.212). High IPI scores have a negative relationship with survival. Multivariate analysis revealed that the type of frontline treatment regimen is an independent factor associated with PFS of PTCL patients (<jats:italic>p<\/jats:italic>=0.045). In the subgroup of patients with high international prognostic index scores (3-5), the HR value for PFS comparing ChT with ChT+C was 4.675.\u00a0A test of interaction between IPI and treatment showed statistical significance (<jats:italic>p<\/jats:italic> = 0.037), implying that the benefits of ChT+C are higher for patients with high IPI scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In summary, the combination of ChT and chidamide may provide a promising prospect for patients with newly diagnosed PTCL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.835103","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T04:35:30Z","timestamp":1643776530000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Jinni","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909","article-title":"Classification of Non-Hodgkin's Lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International Peripheral T-Cell and Natural Killer\/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi037","article-title":"Clinicopathologic Features and Treatment Outcome of Mature T-Cell and Natural Killer-Cell Lymphomas Diagnosed According to the World Health Organization Classification Scheme: A Single Center Experience of 10 Years","volume":"16","author":"Au","year":"2005","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-Cell Lymphoma (Excluding Anaplastic Large-Cell Lymphoma): Results From the Non-Hodgkin's Lymphoma Classification Project","volume":"13","author":"Rudiger","year":"2002","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.12.4514","article-title":"Evaluation of the Revised European-American Lymphoma Classification Confirms the Clinical Relevance of Immunophenotype in 560 Cases of Aggressive Non-Hodgkin's Lymphoma","volume":"89","author":"Melnyk","year":"1997","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab Vedotin With Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Global, Double-Blind, Randomised, Phase 3 Trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the Treatment of Relapsed\/Refractory Peripheral T-Cell Lymphoma: Pivotal Study Update Demonstrates Durable Responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237","article-title":"Results From a Multicenter, Open-Label, Pivotal Phase II Study of Chidamide in Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone Deacetylase Inhibitor (HDACI) Mechanisms of Action: Emerging Insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene Expression Signatures Delineate Biological and Prognostic Subgroups in Peripheral T-Cell Lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-010-0062-x","article-title":"Prognostic Markers in Peripheral T-Cell Lymphoma","volume":"5","author":"Piccaluga","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of Peripheral T-Cell Lymphomas in a Single North American Institution by the WHO Classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): A New Histone Deacetylase Inhibitor of the Benzamide Class With Antitumor Activity and the Ability to Enhance Immune Cell-Mediated Tumor Cell Cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone Deacetylase Inhibitors and the Promise of Epigenetic (and More) Treatments for Cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1073","article-title":"Synergistic Interaction Between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated Through Topoisomerase IIbeta","volume":"11","author":"Marchion","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.42","article-title":"Potentiation of Apoptosis by Histone Deacetylase Inhibitors and Doxorubicin Combination: Cytoplasmic Cathepsin B as a Mediator of Apoptosis in Multiple Myeloma","volume":"104","author":"Cheriyath","year":"2011","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2714","article-title":"Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, With Chemotherapy for the Treatment of Soft Tissue Sarcoma","volume":"15","author":"Lopez","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.835103\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T04:35:34Z","timestamp":1643776534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.835103\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2022.835103"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.835103","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"article-number":"835103"}}